The Flaxil Label (B) Harvard Case Solution & Analysis

This case targets the 2001 dialogue between Mytex Pharmaceuticals and the U.S. Food and Drug Administration (FDA). The results of the dialogue would determine the new label for Mytex's blockbuster drug for arthritis, Flaxil.

The Flaxil Label (B) case study solution

The dialogue is quite qualitative and differs from the typical cost negotiation with which students are familiar. Nevertheless, at position was $500 million in Flaxil sales and safety of millions of patients. The (B) case present the standpoint of a patient and her doctor as they reflect on the new information concerning Flaxil's threat profile.

PUBLICATION DATE: August 24, 2008 PRODUCT #: 909002-HCB-ENG

This is just an excerpt. This case is about LEADERSHIP & MANAGING PEOPLE

The Flaxil Label (B) Case Solution Other Similar Case Solutions like

The Flaxil Label (B)

Share This